title: Comparison of teprenone and famotidine against gastroduodenal mucosal damage in patients taking low-dose aspirin.
abstract: OBJECTIVE
  Proton-pump inhibitors are known to be effective in the treatment and prevention of ulcers related to low-dose aspirin (LDA), but few reports address H2 -receptor antagonists (H2RAs) and gastroprotective agents (GPs). This study was intended to compare the therapeutic effects of an H2RA and a GP against gastroduodenal mucosal injuries in patients taking LDA.
  
  
  METHODS
  The subjects consisted of patients requiring continuous LDA treatment, in whom no peptic ulcer was found on endoscopy at enrollment. The patients were randomized to either famotidine 20 mg/day (group F) or teprenone 150 mg/day (group T). The study medication was administered for 12 weeks. The patients underwent endoscopy after administration of the study medication in order to obtain a Lanza score.
  
  
  RESULTS
  A total of 66 patients (38 in group F, 28 in group T) were included in the efficacy analysis population. The Lanza score changed as follows: in group F, it improved significantly, from 0.89±1.03 (mean±standard deviation) before medication to 0.39±0.75 after medication (P=0.006); in group T, no significant difference was observed: 0.75±0.93 before medication and 0.68±0.82 after medication.
  
  
  CONCLUSIONS
  Famotidine is better than teprenone in terms of reducing the number of the erosions under use of LDA.
authors.affiliation: 2nd Department of Internal Medicine, Osaka Medical College, Osaka, Japan.
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Takeuchi
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Ota
authors.forename: Satoshi
authors.initials: S
authors.lastname: Harada
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kojima
authors.forename: Takuya
authors.initials: T
authors.lastname: Inoue
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Iwakiri
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Sakata
authors.forename: Kazuma
authors.initials: K
authors.lastname: Fujimoto
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Fujita
authors.forename: Takeshi
authors.initials: T
authors.lastname: Azuma
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Higuchi
mesh_terms: D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D004224:Diterpenes / Q000008:administration & dosage*; D015738:Famotidine / Q000008:administration & dosage*; D005260:Female; D006635:Histamine H2 Antagonists / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D004224:Diterpenes; D006635:Histamine H2 Antagonists; D015738:Famotidine; D001241:Aspirin; C031049:geranylgeranylacetone
keywords: famotidine; gastroduodenal injury; low-dose aspirin; teprenone